Zilico Ltd, which is part of the Deepbridge Life Sciences EIS fund, will take centre stage at the World Health Assembly, the decision-making body of WHO (World Health Organisation). It is attended by delegations from all WHO Member States. The main functions of the World Health Assembly are to determine the policies of the Organisation, and review and approve the proposed programme budget. The Health Assembly is held annually in Geneva, Switzerland. 

UK based company, Zilico, which specialises in the design and manufacturing of real-time medical diagnostics to address specific clinical needs. ZedScan™, which is one of Zilico's pioneering flagship products, utilises Electrical Impedance Spectroscopy (E.I.S) to improve the ability to detect Cervical Intraepithelial Neoplasia (CIN) following an abnormal smear result. This device increases diagnostic accuracy and delivers health economic benefits.  

Sameer Kothari, Chief Executive Director of   Zilico  Ltd,  commented:   

“I am very proud that ZedScan is receiving the recognition and the global platform of WHO to showcase the benefits and future potential of this technology to help clinicians, and to produce better outcomes for women and people with cervices’ health the world over. Screening for cervical cancer is important but at the diagnostic stage it is people with abnormal cell changes that need the most accurate attention. ZedScan uses Electrical Impedance Spectroscopy (EIS) which is a different way to analyse tissue structure changes, and it gives results in real time enabling clinicians to better manage their patients.  People are often anxious, and rightly so, during the examination and we know ZedScan helps alleviate some of that anxiety. The real-world data we have published to date shows the potential of this technology not only across mature healthcare markets but also across developing healthcare markets.” 

The patented E.I.S technology exploits the different electrical resistivity associated with the cellular structure of normal, pre-cancerous and cancerous tissue, which based on its applicability to other types of neoplasia, substantiates its use as a platform for the rapid, reliable and reproducible detection and diagnosis of disease.  

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).